Registered Attendees

Registered Attendees

Print This Page

Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online before the meeting...these abstracts will be available in the Abstract Book at the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

Close Window
Fairmont Chateau Whistler Floorplan

Fairmont Chateau Whistler Floorplan

Print This Page



Close Window

This meeting took place in 2013



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Immunopathology of Type 1 Diabetes (Z1)


Organizer(s) Kevan C. Herold, Dario A.A. Vignali, Jeffrey A. Bluestone and Anne Cooke
April 4—9, 2013
Fairmont Chateau Whistler • Whistler, British Columbia Canada
Abstract Deadline: Dec 4, 2012
Late Abstract Deadline: Jan 4, 2013
Scholarship Deadline: Dec 4, 2012
Early Registration Deadline: Feb 4, 2013

Supported by the Directors' Fund


Summary of Meeting:
A great deal has been learned about the effectors and mechanisms of Type 1 diabetes from preclinical models and studies of samples from patients at risk and with the disease. However, despite this progress, translation of this understanding into new therapies that will have impact on patients has not been realized. The Keystone Symposia meeting on Immunopathology of Type 1 Diabetes will review our understanding of the mechanisms that are involved in the disease with consideration of the ways in which this understanding has resulted in clinical translation and how it has failed. Our goal is to integrate the most up to date understanding of mechanisms of autoimmune diabetes with studies in patients in order to identify ways in which developments in preclinical studies can provide insight into the past experiences in clinical studies and improve the design of future studies. The meeting will explore the following areas in detail: 1) What are the genetic determinants, immunopathology, and triggers of the disease? 2) What are the immune effectors that lead to beta cell destruction – how do they form and what are their functional characteristics? 3) How are immune effectors controlled in healthy individuals and how does this control fail in T1DM? 4) What has been the experience in restoring immune tolerance in humans – how can this be improved in the future? Opportunities for interdisciplinary interactions will be significantly enhanced by the concurrent meeting on Advances in the Knowledge and Treatment of Autoimmunity, which will share a keynote address and two plenary sessions with this meeting.

View Scholarships/Awards

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


THURSDAY, APRIL 4

15:00—19:30
Arrival and Registration

18:15—19:15
Refreshments

19:15—21:30
Welcome and Keynote Session (Joint)
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* Kevan C. Herold, Yale University, USA
Welcome Remarks

* Juan Rivera, , USA

Luke A. J. O'Neill, Trinity College Dublin, Ireland
Innate Immunity, Autoinflammation and Autoimmunity

* Dario A. A. Vignali, University of Pittsburgh School of Medicine, USA

Diane J. Mathis, Harvard Medical School, USA
Anti-Inflammatory Macrophages Regulate the Progression of T1D


FRIDAY, APRIL 5

07:00—08:00
Breakfast

08:00—11:30
Modulation of Immunity toward Autoimmune Therapy: From Mouse to Man (Joint)
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

NOTE: The focus of this session is on the regulatory networks controlling immune response and the modulation of these processes towards amelioration of autoimmune disease.

* Pere Santamaria, University of Calgary, Canada

Dario A. A. Vignali, University of Pittsburgh School of Medicine, USA
Molecular Control of Treg Stability and Function

Arlene H. Sharpe, Harvard Medical School, USA
Control of Humoral Immunity by Lymph Node and Blood T Follicular Regulatory Cells

Alexander V. Chervonsky, University of Chicago, USA
Microbial Influence on Type 1 Diabetes

Jon D. Piganelli, University of Pittsburgh, Children's Hospital, USA
Short Talk: Modulating the Bioenergetics of a Diabetogenic Immune Response

Stephen D. Miller, Northwestern University Medical School, USA
Induction of Immune Tolerance in the Treatment of Autoimmunity

Maria Grazia Roncarolo, San Raffaele Scientific Institute, Italy
Adaptive Immune Therapy with Regulatory T Cells for the Treatment of Autoimmunity

09:20—09:40
Coffee Break

11:30—13:00
Poster Setup

13:00—22:00
Poster Viewing

11:30—16:30
On Own for Lunch and Recreation

16:30—17:00
Coffee Available

17:00—19:00
Immune Effector/Autoantigens in T1DM
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* Bart O. Roep, Leiden University Medical Center, Netherlands

Emil R. Unanue, Washington University School of Medicine, USA
Identifying Early Cellular and Genetic Events in NOD Diabetogenesis

Teresa P. DiLorenzo, Albert Einstein College of Medicine, USA
Antigen-Specific T Cells in NOD Mouse Models of Diabetes

Rachel S. Friedman, National Jewish Health and University of Colorado, Denver, USA
Short Talk: T Cell Restimulation through Synaptic Contacts at the Autoimmune Disease Site Drives Effector Cytokine Production

Mark Peakman, King's College London, UK
Pathogenic T Cells in Human T1D

17:00—19:00
Mechanisms of Peripheral and Central Tolerance
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

John W. Kappler, HHMI/National Jewish Health, USA
Defining the Structural Nature of the Pathogenic CD4 T cell Ligands in NOD Type 1 Diabetes

* Kristin V. Tarbell, NIDDK, National Institutes of Health, USA
Diabetes, Dendritic Cells, and Induction of T Cell Tolerance

Shannon J. Turley, Genentech, USA
Interactions of DCs and T Cells with Lymphoid Stroma

Brian D. Stadinski, University of Massachusetts Medical School, USA
Short Talk: TCRalpha to TCRbeta Interactions Control Peptide Specificity and Self-Tolerance

19:00—20:00
Social Hour with Lite Bites

19:30—22:00
Poster Session 1


SATURDAY, APRIL 6

07:00—08:00
Breakfast

08:00—11:30
Regulatory and Developmental Control of T1DM
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* Matthias G. von Herrath, Novo Nordisk, USA

Mark S. Anderson, University of California, San Francisco, USA
Immune Tolerance Mediated by Extrathymic Aire

Stephan Kissler, Joslin Diabetes Center, USA
Short Talk: The Type 1 Diabetes-Associated Gene CLEC16A Modulates Thymic Epithelial Cell Function and Impacts Central Tolerance

Jeffrey A. Bluestone, University of California, San Francisco, USA
Regulatory T Cells: Controlling Your (Immune) Temper

Pere Santamaria, University of Calgary, Canada
Maturation and Modulation of CD8+ T Effector Cells

Jane H. Buckner, Benaroya Research Institute at Virginia Mason, USA
T Cell Deregulation in Human T1DM

David A. Hafler, Yale University School of Medicine, USA
Common Non-Coding Variation at Enhancers Reveals Multi-lineage Contribution to Human Autoimmune Disease

08:00—11:15
Innate Immunity and Autoimmune Disease
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

NOTE: Explores how innate immune cells play a role in the initiaition and progression of autoimmunity.

* Silvia Bolland, NIAID, National Institutes of Health, USA
TLR7-Induced NK Innate Lymphoid Cells

Virginia Pascual, Baylor Institute for Immunology Research, USA
Novel Myeloid Cell B Helper Pathways in SLE

Juan Rivera, , USA
Auto-Reactive IgE and Basophils in the Amplification of SLE

Melissa A. Brown, Northwestern University, USA
Mast Cells in the Meninges: Orchestrators of Early Inflammation in CNS Disease

Roland W. Kolbeck, MedImmune, LLC, USA
Short Talk: LC3 Associated Phagocytosis Mediates IFNalpha Secretion in Response to DNA-Immune Complexes

Carla M. Cuda, Northwestern University, USA
Short Talk: Caspase 8 Limits Dendritic Cell Activation

11:30—12:30
NIDDK Workshop: When is a Mechanism not a Mechanism? NIH Advice for Young Investigators

* Lisa Spain, NIDDK, National Institute of Health, USA

09:20—09:40
Coffee Break

11:30—13:00
Poster Setup

13:00—22:00
Poster Viewing

11:30—16:30
On Own for Lunch and Recreation

16:30—17:00
Coffee Available

17:00—19:00
Workshop 1: Basic Research Advances

* Anne Cooke, University of Cambridge, UK

Imran S. Khan, University of California, San Francisco, USA
MicroRNA Regulation of Thymic Epithelial Cell Biology and Central Tolerance

Yong Fan, University of Pittsburgh, USA
ID-TEC and ID-TEC-Rag Mice, Novel Animal Models for Studying Insulin Autoimmunity in Type 1 Diabetes

Maria Bettini, St. Jude Children's Research Hospital, USA
TCR Affinity Shapes T Cell Pathogenicity and Susceptibility to Tolerance Mechanisms

Allyson M. Spence, University of California, San Francisco, USA
Regulatory T Cell Commitment and Destabilization in the Inflamed Islets of NOD Mice

Lindsey E. Padgett, University of Alabama, Birmingham, USA
Reactive Oxygen Species Modulate CD4 T Cell Effector Responses in T1D

Karmel Allison, University of California, San Diego, USA
Genome-Wide Sequencing of Nascent Transcripts in NOD Mouse Macrophages Reveals New Mechanisms of Innate Immune Disregulation in Type 1 Diabetes

Rochelle M. Hinman, National Jewish Health, USA
Function and Fate of Insulin Reactive B Cells in Type 1 Diabetes

Eliana Marino, Monash University, Australia
A Strong Gut Feeling about the Cause of Type 1 Diabetes

17:00—19:00
Challenges and Lessons from Immunotherapy
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

NOTE: This session explores how identification of biomarkers and new treatments are advancing our knowledge of mechanisms and the pathophysiology underlying autoimmune disease and explores the challenges faced in the development and use of therapies in autoimmunity

* Timothy W. Behrens, Genentech, Inc., USA
Personalizing Medicine for Autoimmune and Inflammatory Diseases

Atul J. Butte, Stanford University, USA
Transforming 300 Billion Points of Data into Diagnostics, Therapeutics, and New Insights into Immunological Disease

Robert P. Anderson, ImmusanT, Inc., USA
Celiac Disease - Can We Transition from Peptides to Treatment?

Steven D. Levin, Novo Nordisk, USA
Short Talk: IL21 Contributes to Human Autoimmune Disease through Multiple Mechanisms and IL21 Neutralization has Beneficial Effects in vitro

17:00—19:00
Workshop 2: Translational/Clinical Research Advances

* Kevan C. Herold, Yale University, USA

Matthew M. Rankin, Children's Hospital of Philadelphia, USA
Increased Islet Replication and Persistent Insulitis in Pancreata from Adolescent T1D Patients

Gaetano Faleo, University of California, San Francisco, USA
Protection of Allogeneic Cells from Alloimmune-Mediated Rejection Using Macroencapsulation

Melanie Stumpf, University of Colorado Denver, USA
Identification of Disease-Associated TCR alpha and beta Chains Directly from Pancreas Tissue of T1D Patients

Nalini K. Vudattu, Yale University, USA
The Study of Autoimmune Disease in Humanized Mice

Rachel H. Bonami, Vanderbilt University, USA
Autoantigen-Targeted Therapy: Stopping Anti-Insulin B Cells from Giving T Cells Bad Advice

Brian T. Fife, University of Minnesota, USA
Indirect Presentation of Antigen-Coupled Cells Mediates Specific CD4+ T Cell Tolerance for the Prevention of T1D

Sofie Robert, KU Leuven, Belgium
Islet Autoantigens Delivered by L. lactis in the Gut Together with hIL-10 Revert Diabetes in Recent-Onset NOD Mice when Combined with Low-Dose Anti-CD3

Michael D. McHugh, Yale University, USA
Induction of Tolerance in Type 1 Diabetes Using Biodegradable Nanoparticles

19:00—20:00
Social Hour with Lite Bites

19:30—22:00
Poster Session 2


SUNDAY, APRIL 7

07:00—08:00
Breakfast

08:00—11:30
The Microflora in the Regulation of Immunity and Autoimmunity (Joint)
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

NOTE: Reviews recent advance on the microbiomes influence in initiation, progression, and regulation of immune responses and autoimmune disease.

George M. Weinstock, Washington University School of Medicine, USA
Overview of the Human Microbiome: A New Frontier that just Might Affect Everything

* Jayne S. Danska, Hospital for Sick Children Research Institute, Canada
The Gut Microbiome Drives Hormone-Dependent Regulation of Type 1 Diabetes

Fiona M. Powrie, University of Oxford, UK
Microbiome-Induced IL-23 Promotes Intestinal Inflammation and Colon Cancer

Mark A. Atkinson, University of Florida, USA
The Role for the Gut Microbiome in Type 1 Diabetes – Early Lessons from Humans and NOD Mice

Joseph Larkin III, University of Florida, USA
Short Talk: Antigen Presenting Cell Interactions with Gut Flora Modulate Diabetogenic T Lymphocyte Effector Functions

Lloyd H. Kasper, Geisel School of Medicine at Dartmouth, USA
Role of Commensal Bacteria in the Regulation of Central Nervous System Disease Demyelination

09:20—09:40
Coffee Break

11:30—13:00
Poster Setup

13:00—22:00
Poster Viewing

11:30—16:30
On Own for Lunch and Recreation

14:30—16:30
Workshop 1: Basic Mechanisms in Autoimmunity

* Shannon J. Turley, Genentech, USA

Rachel R. Caspi, NEI, National Institutes of Health, USA
IL-27p28 Inhibits CNS Autoimmunity by Concurrently Antagonizing Th1 and Th17 Responses

Tian Chi, Yale University, USA
BRG1-Mediated Immune Tolerance: Facilitation of Treg Activation and Partial Independence of Chromatin Remodeling

Benoit L. Salomon, University Pierre et Marie Curie, France
TNFalpha /TNFR2 Pathway Is Critical for EAE Remission and Treg Expansion in the Central Nervous System

Jianmei W. Leavenworth, Dana-Farber Cancer Institute, USA
Amelioration of Arthritis through Mobilization of Peptide-Specific CD8+ Regulatory T-Cells

Natalia V. Giltiay, Washington University, USA
Antigen Delivery to pDCs through hBDCA2 Leads to Reduction of Effector T-Cell Activation and Ag-Specific Ab Responses

Rajat Varma, LSB, NIAID, National Institutes of Health, USA
T Cell Receptor Microclusters are Platforms for Ligand Discrimination

14:30—16:30
Workshop 2: Clinical and Translational Aspects of Autoimmunity

* Jane H. Buckner, Benaroya Research Institute at Virginia Mason, USA

Simone Caielli, Baylor Institute for Immunology Research, USA
SLE Neutrophil-Derived DAMPs Activate pDCs to Induce a Lupus-Specific CD4 T Cell Phenotype

Barbara Dema, NIAMS, National Institutes of Health, USA
Prevalence of Auto-Reactive IgE and Activated Basophils in Systemic Lupus Erythematosus

Gabriela Hernandez-Hoyos, Emergent BioSolutions (EBSI), USA
A Bi-Specific ADAPTIR Molecule that Targets CD86 and Delivers IL-10 Inhibits Antigen Presenting Cells and Has Potential as a Therapeutic Treatment of Autoimmune Disease

Silvia Preite, Institute for Research in Biomedicine, Switzerland
Regulation of T Helper Cell-Dependent Antibody Response in Lymphopenic Hosts

Yasuko Furumoto, NIAMS, National Institutes of Health, USA
Tofacitinib Inhibits Cell Metabolism in Activated T Cells

Catia Verbeke, Harvard University, USA
Antigen-Specific Immune Modulation Using an Injectable Biomaterial

16:30—17:00
Coffee Available

17:00—19:00
Immune Modulation and Effects of Immune Modulators on T1DM
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* Fiona M. Powrie, University of Oxford, UK

Matthias G. von Herrath, Novo Nordisk, USA
Learning from Human Immunopathology to Develop Rational Treatments for Type 1 Diabetes

Lucienne Chatenoud, INSERM U1013, Hôpital Necker-Enfants Malades, France
CD3 Antibodies in Established Autoimmunity: A Glass Half Empty or Half Full?

Thomas R. Malek, University of Miami School of Medicine, USA
Short Talk: Human T Regulatory Cells Are Intrinsically More Sensitive to IL-2-Induced Signal Transduction Than T Effector and T Memory Cells

Bart O. Roep, Leiden University Medical Center, Netherlands
Methods and Mechanisms of Immune Modulation in Humans

17:00—19:00
Lymphocytes in Autoimmunity I - B Cells
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

NOTE: Covers recent advances on B cells as promoters and regulators of immune responses and autoimmunity.

* David M. Lee, Novartis Institutes for Biomedical Research, Switzerland

Eric Meffre, Yale University School of Medicine, USA
Impact of Gene Mutations and Polymorphisms on Human B-Cell Tolerance

Andreas Radbruch, Deutsches Rheuma-Forschungszentrum, Berlin, Germany
Plasmablasts vs. Plasma Cells - Roles in Autoantibody Production

Thomas F. Tedder, Duke University Medical Center, USA
Regulatory B Cells in Health and Disease: B10 Cells Negatively Regulate Autoimmunity

Mohini K. Gray, MRC Centre for Inflammation Research, Scotland
Short Talk: A Tolerogenic Role for Toll-Like Receptor 9 Is Revealed by Regulatory B-Cell Interaction with Apoptotic Cells

19:00—20:00
Social Hour with Lite Bites

19:30—22:00
Poster Session 3


MONDAY, APRIL 8

07:00—08:00
Breakfast

08:00—11:30
Cellular and Environmental Networks in T1DM
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* Dario A. A. Vignali, University of Pittsburgh School of Medicine, USA

Li Wen, Yale University, USA
Role of TLRs in Regulation of Autoimmunity and Beta Cells in Type 1 Diabetes

Anne Cooke, University of Cambridge, UK
Epigenetic Modification of Induced Treg Cells: Implications for Therapy

Agnès C. Lehuen, Hôpital Saint Vincent de Paul, France
NKT Cells and Plasmacytoid DC in Type 1 Diabetes in Infectious and Non-Infectious Context

David V. Serreze, The Jackson Laboratory, USA
To Be or Not To Be: Challenges in B-Lymphocyte Directed Interventions for Autoimmune Diabetes

Lucy S. K. Walker, University College London, UK
Short Talk: Roles for IL-21 in Modulating T and B Cell Immunity in Autoimmune Diabetes

Megan K. Levings, University of British Columbia, Canada
Molecular and Functional Properties of Regulatory T Cells

08:00—11:15
Lymphocytes in Autoimmunity II - T Cells
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

NOTE: Discussion of T cell function in immunity and autoimmunity with emphasis on human immunology.

Federica Sallusto, Institute for Research in Biomedicine, Universtà della Svizzera Italiana, Switzerland
T Cell Subsets in Human Disease

Shigeo Koyasu, Keio University School of Medicine, Japan
Role of Natural Helper Cell, a Member of the ILC (ILC2) in Steroid Resistance of Allergic Inflammation

* Carola G. Vinuesa, Australian National University, Australia
Control of Tfh Cells

Vijay K. Kuchroo, Brigham and Women's Hospital, Harvard Medical School, USA
Unexpected Targets and Triggers of Autoimmunity

Xuezhi Dai, Seattle Childrens' Research Institute, USA
Short Talk: The PTPN22 Risk Variant Promotes Systemic Autoimmunity in Murine Models

Anne R. Gocke, Johns Hopkins University, USA
Short Talk: Kv1.3 Deletion Induces Foxo1 Expression and Biases TH Cells Toward an Immunoregulatory Phenotype Independently of Foxp3

11:30—12:30
NIDDK Planning Meeting: Future Needs and Priorities for Type 1 Diabetes Research

* Beena Akolkar, NIDDK, National Institutes of Health, USA

09:20—09:40
Coffee Break

11:30—16:30
On Own for Lunch and Recreation

16:30—17:00
Coffee Available

17:00—19:00
The Future of T1DM Research and Clinical Translation
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

* Jeffrey A. Bluestone, University of California, San Francisco, USA

Linda S. Wicker, University of Cambridge, UK
IL-2 Therapy for Type 1 Diabetes

Paul L. Bollyky, Stanford University, USA
Short Talk: Hyaluronan Promotes Tonic STAT5 Signaling in Human Treg But this Effect Is Impaired in Type 1 Diabetes

Kevan C. Herold, Yale University, USA
Combination Therapies for Type 1 Diabetes

Gerald T. Nepom, Benaroya Research Institute, USA
Next-Generation Therapeutic Opportunities and Challenges in T1D

17:00—19:00
Systems Approaches to Autoimmunity
Meeting has ended...abstracts no longer viewable online. Purchase an Abstract Book from this meeting

NOTE: What information is being gained by a systems approach toward the study of autoimmunity and how can we best utilize these vast data sets?

* Virginia Pascual, Baylor Institute for Immunology Research, USA

Nir Hacohen, Massachusetts General Hospital, USA
Deficiencies in DNases Lead to Autoimmunity

Edward K. Wakeland, University of Texas Southwestern Medical Center, USA
Genomic Analysis of Susceptibility to Autoimmunity

Soumya Raychaudhuri, Brigham and Women's Hospital, Harvard Medical School, USA
Genetics, Epigenetics, and Functional Genomics to Identify Critical Host Cell-Types in Autoimmunity

Bernd Wollscheid, ETH Zürich, Switzerland
Short Talk: Caught in the Act: LCR Technique for the Direct Identification of Endogenous Ligand-Receptor Interaction on Cells and Tissue

19:00—20:00
Social Hour with Lite Bites

20:00—23:00
Entertainment


TUESDAY, APRIL 9

 
Departure


*Session Chair †Speaker invited, not yet responded.



We gratefully acknowledge additional support for this conference from:

JDRF

We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1R13DK098937-01

The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Amanda Deem, Assistant Director of Development, Email: AmandaD@keystonesymposia.org,
Phone:+1 970-262-2668

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676